Cargando…

A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate

We have previously shown that tamoxifen+epigallocatechin gallate (EGCG) is synergistically cytotoxic towards oestrogen receptor (ER)-negative breast cancer cells. To determine if this response would correlate with significant tumour suppression in vivo, athymic nude female mice were implanted with M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scandlyn, M J, Stuart, E C, Somers-Edgar, T J, Menzies, A R, Rosengren, R J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567064/ https://www.ncbi.nlm.nih.gov/pubmed/18797454 http://dx.doi.org/10.1038/sj.bjc.6604634

Ejemplares similares

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
por: Legrier, Marie-Emmanuelle, et al.
Publicado: (2016)

Regulation of tamoxifen sensitivity by a PAK1–EBP1 signalling pathway in breast cancer
por: Ghosh, A, et al.
Publicado: (2013)

An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen
por: Andersen, T T, et al.
Publicado: (2007)

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
por: McCloy, R A, et al.
Publicado: (2013)

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death
por: Obiorah, I, et al.
Publicado: (2014)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
por: Dubrovska, A, et al.
Publicado: (2012)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
por: Lunt, S J, et al.
Publicado: (2010)

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
por: Steele, N, et al.
Publicado: (2009)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

α-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate
por: Tomasetti, M, et al.
Publicado: (2010)

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
por: Meira, D D, et al.
Publicado: (2009)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination
por: Huang, H, et al.
Publicado: (2014)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
por: Eicher, C, et al.
Publicado: (2013)

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant
por: Shimizu, Y, et al.
Publicado: (2008)

Immune activation by combination human lymphokine-activated killer and dendritic cell therapy
por: West, E J, et al.
Publicado: (2011)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

Profilin-1 is a negative regulator of mammary carcinoma aggressiveness
por: Zou, L, et al.
Publicado: (2007)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia
por: Faber, J, et al.
Publicado: (2008)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
por: Di Mauro, Concetta, et al.
Publicado: (2017)

The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis
por: Follet, J, et al.
Publicado: (2012)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
por: Siveen, K S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e5us8f8hlstmkqihpj11pgf50o